URANIS -Data Collection in Urological Centers During Treatment With Ra-223 Dichloride (Xofigo) Within the Framework of a Non-interventional Study Assessing Overall Survival (OS) and Effectiveness Predictors of Ra- 223 Dichloride (Xofigo) Treated Chemotherapy naïve mCRPC Patients in a Real Life Setting in Germany

Trial Profile

URANIS -Data Collection in Urological Centers During Treatment With Ra-223 Dichloride (Xofigo) Within the Framework of a Non-interventional Study Assessing Overall Survival (OS) and Effectiveness Predictors of Ra- 223 Dichloride (Xofigo) Treated Chemotherapy naïve mCRPC Patients in a Real Life Setting in Germany

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms URANIS
  • Sponsors Bayer
  • Most Recent Events

    • 15 Mar 2017 Planned number of patients changed from 500 to 250.
    • 15 Mar 2017 Planned End Date changed from 1 Jan 2020 to 30 Jun 2021.
    • 15 Mar 2017 Planned primary completion date changed from 1 Nov 2019 to 31 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top